SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Dec. 27, 2023

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Outlook investors who were adversely affected by alleged securities fraud between December 29, 2022 and August 29, 2023. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/outlook-lawsuit-submission-form?prid=61386&wire=4

OTLK investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) there was a lack of substantial evidence supporting the Company's lead product candidate, ONS-5010, as a treatment for wet age-related macular degeneration; (ii) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls and other manufacturing issues for ONS-5010, which remained unresolved at the time the ONS-5010 biologics license application ("BLA") was resubmitted to the U.S. Food and Drug Administration ("FDA"); (iii) as a result of all the foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its present form; (iv) accordingly, ONS-5010's regulatory and commercial prospects were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Outlook during the relevant time frame, you have until January 2, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.